Jonathan G. Drachman

Jonathan G. Drachman is a declared insider at 3 companies (chief executive); the most frequent names are Harpoon Therapeutics, Inc., Neurogene Inc. and Calithera Biosciences, Inc. Over a trading history stretching from 3 June 2021 to 8 March 2024, the count stands at 5 filings.

The open-market record is one-sided, with 3 purchases worth €833k and not one sale. No amount is published for 1 filing, which the totals therefore leave out. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Besides market trades, the filings include 2 share grants.

Most recently, on 11 March 2024, the filings show a share grant in Harpoon Therapeutics, Inc. The last insider purchase was made public on 10 November 2021, 1,803 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. The legal deadline for a Form 4 is two business days after the transaction. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.